Your browser doesn't support javascript.
loading
A biomarker study in Peruvian males with breast cancer.
Castaneda, Carlos A; Castillo, Miluska; Bernabe, Luis A; Sanchez, Joselyn; Torres, Ebert; Suarez, Nancy; Tello, Katherine; Fuentes, Hugo; Dunstan, Jorge; De La Cruz, Miguel; Cotrina, Jose Manuel; Abugattas, Julio; Guerra, Henry; Gomez, Henry L.
Afiliación
  • Castaneda CA; Faculty of Health Sciences, Universidad Cientifica del Sur, Lima 15067, Peru.
  • Castillo M; Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Bernabe LA; Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Sanchez J; Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Torres E; Department of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Suarez N; Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Tello K; Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Fuentes H; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Dunstan J; Department of Breast Cancer Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • De La Cruz M; Department of Breast Cancer Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Cotrina JM; Department of Breast Cancer Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Abugattas J; Department of Breast Cancer Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Guerra H; Department of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
  • Gomez HL; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
World J Clin Oncol ; 12(10): 926-934, 2021 Oct 24.
Article en En | MEDLINE | ID: mdl-34733614
ABSTRACT

BACKGROUND:

Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC.

AIM:

To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population.

METHODS:

This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves.

RESULTS:

The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative (P = 0.018) but not with ER (P = 0.43) or TIL (P = 0.84). Early stages (P < 0.001) and lower grade (P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival (P > 0.05).

CONCLUSION:

Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: World J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Perú

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: World J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Perú